Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...
Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA inter...
Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-...
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, c...
Andreessen Horowitz (a16z) Bio + Health announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health...
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...
Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, announced the c...
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic ...
An indictment unsealed on charged the former chief scientific officer of biopharmaceutical company Humanigen (0KB2.BE), opens new tab with engagi...
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancer...
BD (Becton, Dickinson and Company) , a leading global medical technology company, issued the following statement: BD has reached an agreement with...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: ...
© 2025 Biopharma Boardroom. All Rights Reserved.
